Evercore ISI Group analyst Jonathan Miller initiates coverage on ProKidney (NASDAQ:PROK) with a Outperform rating.
Geron Q2 EPS $(0.07) Beats $(0.09) Estimate, Sales $73.00K Miss $110.00K Estimate
Geron (NASDAQ:GERN) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 22.22 percent increase over losses of $(0.09) per share from the same
